Gene Editing beyond CRISPR Market, Industry Trends and Global Forecasts, 2022-2035
With the approval of HUMULIN®, the first
genetically modified drug, scientific community has made significant progress
in developing gene edited therapies based on programmable nucleases, such as
ZFNs, TALENs, EMNs and CRISPR
London
Roots
Analysis has announced the addition of “Gene-Editing
Beyond CRISPR: Focus on ZFN, TALENs and Meganucleases Market,
2021-2035” report to its list of offerings.
The ability of gene editing solutions to directly target
and modify genomic sequences has greatly expedited the progress of gene editing
therapies into clinical stages. The clinical trials data of ZFNs, TALENs and
meganucleases based therapies demonstrate their potential in the treatment of
various diseases, including infectious diseases and oncological disorders. In
addition, several product candidates are being evaluated in discovery and
preclinical stages of development for hematological disorders, genetic
disorders and neurological disorders.
To order this 150+ page report, which features 100+
figures and 5+ tables, please visit
https://www.rootsanalysis.com/reports/gene-editing-market.html
Key Market Insights
Presently, close to 50 drug candidates are being
evaluated across different phases of development
More than 40% of the drugs have reached clinical stage of
development; of these, one drug named ZFN-758 has entered the phase II stage.
This is followed by 57% drugs which are being investigated in preclinical and
discovery stages.
More than 1,300 patients have been enrolled in over
28 clinical trials, worldwide
Clinical research activity, in terms of number of trials
registered, is reported to have increased in the last five years. Of the total
number of trials, more than 30% have already been completed, while 56% are
active and still recruiting patients.
Close to 1,300 articles focused on ZFN, TALENs and
Meganucleases have been published, since 2016
Owing to the rising research efforts led by several
industry and non-industry players in this domain, a number or peer reviewed
articles have been published in reputed scientific journals. It is worth
highlighting that, in 2021 (till June) 561 articles related to TALENs were
published.
Close to 20 partnerships have been inked among
various industry and non-industry players
The maximum number of partnerships were established in
2021, indicating a recent rise in the interest of players involved in this
domain. It is worth highlighting that, majority of the deals were licensing
agreements, representing over 28% of the total number of partnerships signed
followed by research and development (18%), research, development and
commercialization (18%), product development and commercialization (12%),
product development (12%) and clinical trial (12%) agreements.
Close to USD 1.8 billion has been invested by both
private and public investors, since 2000
Of the total amount invested, over USD 884 million was
raised through initial public offering (IPO), representing over 48% of the
overall funding activity in this domain. Further, six instances of venture
capital funding were also reported, wherein players collectively received more
than USD 450 million.
The primary source of income for gene editing
technology providers is anticipated to be out-licensing deals
North America is likely to capture the maximum share in the
global market, followed by Europe and Asia Pacific (in terms of revenue
generated from technology licensing). The market in these regions is
anticipated to grow at a CAGR of 18% between 2022-2035.
To request a sample copy / brochure of this report,
please visit
https://www.rootsanalysis.com/reports/gene-editing-market/request-sample.html
Key Questions Answered
- Who
are the players engaged in the development of gene editing therapies
beyond CRISPR?
- Which
are the key drugs being developed across early and late stages of
development?
- Which
companies are actively involved in conducting clinical trials for ZFNs,
TALENs and Meganucleases based therapies?
- What
is the focus area of various publications related to ZFNs, TALENs and
Meganucleases based therapies?
- What
kind of partnership models are commonly adopted by industry stakeholders?
- What
is the trend of capital investments in the gene editing beyond CRISPR
market?
- How
has the intellectual property landscape related to ZFNs, TALENs and
Meganucleases based therapies evolved over the years?
- How
is the current and future opportunity, related to ZFNs, TALENs and
Meganucleases based therapies, likely to be distributed across key market
segments?
The financial opportunity within the gene editing
technologies market has been analyzed across the following key geographical
regions, including:
- North
America
- Europe
- Asia
Pacific
The research includes detailed profiles of key players
(listed below) engaged in the development of gene editing technologies; each
profile features an overview of the company, its financial information (if
available), details on product portfolio, recent developments, and an informed
future outlook.
- Allogene
Therapeutics
- bluebird
bio
- Cellectis
- Cytovia
Therapeutics
- Iovance
Biotherapeutics
- Precision
Biosciences
- Sangamo
Therapeutics
For additional details, please visit
https://www.rootsanalysis.com/reports/gene-editing-market.htmlor
email sales@rootsanalysis.com
You may also be interested in the following titles:
- CRISPR
based Therapeutic Market by Type of Therapy, 2021-2030
- Gene
Editing Services Market- Focus on CRISPR, 2019-2030
Contact:
Ben Johnson
+1 (415) 800 3415
Comments
Post a Comment